Literature DB >> 26005012

Assessment of mucosal healing in inflammatory bowel disease: review.

Parambir S Dulai1, Barrett G Levesque1, Brian G Feagan2, Geert D'Haens3, William J Sandborn1.   

Abstract

BACKGROUND AND AIMS: Mucosal healing is an important treatment end-point in inflammatory bowel disease, and achieving mucosal healing has been demonstrated to improve disease-related outcomes. Considerable uncertainty exists, however, regarding the optimal approach for the assessment of mucosal healing. AIMS: To compare currently available diagnostic tools for the assessment of mucosal healing and outline the ideal approach to integrating these tools into clinical trials and clinical practice.
METHODS: Review article.
RESULTS: Endoscopy represents the criterion standard for the assessment of mucosal healing, and frequent endoscopic assessment is associated with a higher rate of achieving mucosal healing. The use of mucosal biopsy allows for the identification of persistent histologic disease activity, but the incremental clinical benefit of achieving histologic healing is yet to be determined. Magnetic resonance enterography has a high sensitivity for ulcer healing in endoscopically inaccessible disease activity. However, the presence of mucosal lesions cannot be reliably excluded based on this modality alone, and further small-bowel endoscopy should be considered in symptomatic patients. Video capsule endoscopy or device-assisted enteroscopy can be used, with device-assisted enteroscopy being preferred in stricturing Crohn's disease because of the risk of capsule retention or in patients in whom small-bowel malignancy is a possibility.
CONCLUSIONS: Endoscopy remains the criterion standard for the assessment of mucosal healing. Several alternative diagnostic modalities have become available that can be of value in specific clinical circumstances, particularly in patients with small-bowel involvement.
Copyright © 2015 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26005012      PMCID: PMC6709676          DOI: 10.1016/j.gie.2015.03.1974

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  31 in total

Review 1.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 2.  Video capsule endoscopy in inflammatory bowel disease.

Authors:  Paul D Collins
Journal:  World J Gastrointest Endosc       Date:  2016-07-25

Review 3.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

Review 4.  Current role of capsule endoscopy in Crohn's disease.

Authors:  Marisol Luján-Sanchis; Laura Sanchis-Artero; Laura Larrey-Ruiz; Laura Peño-Muñoz; Paola Núñez-Martínez; Génesis Castillo-López; Lara González-González; Carlos Boix Clemente; Cecilia Albert Antequera; Ana Durá-Ayet; Javier Sempere-Garcia-Argüelles
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

Review 5.  Next-Generation Therapeutics for Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; William J Sandborn
Journal:  Curr Gastroenterol Rep       Date:  2016-09

6.  Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease.

Authors:  Maria Barsky; Joseph Meserve; Helen Le; Angelina Collins; Siddharth Singh; Brigid Boland; William J Sandborn; Parambir S Dulai
Journal:  Dig Dis Sci       Date:  2020-09-01       Impact factor: 3.199

Review 7.  Acute severe ulcerative colitis: latest evidence and therapeutic implications.

Authors:  Parambir S Dulai; Vipul Jairath
Journal:  Ther Adv Chronic Dis       Date:  2017-11-24       Impact factor: 5.091

Review 8.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

9.  US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.

Authors:  Berkeley N Limketkai; Siddharth Singh; Vipul Jairath; William J Sandborn; Parambir S Dulai
Journal:  Inflamm Bowel Dis       Date:  2019-10-18       Impact factor: 5.325

Review 10.  Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.

Authors:  Bram Verstockt; Nurulamin M Noor; Urko M Marigorta; Polychronis Pavlidis; Parakkal Deepak; Ryan C Ungaro
Journal:  J Crohns Colitis       Date:  2021-09-25       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.